Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

Gilead Sciences, Inc.Trade
VanEck Rare Earth/Strategic MetalsTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? Gilead Sciences, Inc. trades at $136.02 (market cap $168.35B), while VanEck Rare Earth/Strategic Metals trades at $77.15. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while VanEck Rare Earth/Strategic Metals pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.

GILDREMX
Market Cap
$168.35B
Sector
HealthSector/Thematic
52-Week High
$155.80$109.53
52-Week Low
$110.56$56.60
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

VanEck Rare Earth/Strategic Metals

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.52, down 1.19% today. The technical outlook is bullish based on moving averages, with a neutral oscillator reading. Recent news highlights U.S. efforts to build rare earth supply chain independence, with construction starting on Energy Fuels' Utah plant expansion (Forbes, 2026-08-04). The ETF provides exposure to 38 global rare earth companies but exhibits high volatility (~50% annualized) and turnover.

The long-term outlook for REMX is supported by geopolitical shifts and demand for critical minerals in technology and defense. However, risks include high volatility, China's dominance in the sector, and sensitivity to trade policies. Investors should weigh the growth potential against the ETF's speculative nature and lack of traditional fundamental metrics like P/E or P/S ratios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About VanEck Rare Earth/Strategic Metals

REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.

Read more on REMX